Cargando…

568. The Impact of Disclosure Stigma on Virologic Outcomes in People Living with HIV

BACKGROUND: HIV-related stigma is a leading barrier to engagement in HIV care and successful treatment. Disclosure Stigma (DS), the fear of disclosing one’s serostatus, is associated with poor adherence and retention in care, but its association with clinical indicators of HIV treatment is not well...

Descripción completa

Detalles Bibliográficos
Autores principales: Matheu, Michelle, Gleason, Laurie, Sunil, Thankam, Castro-Pena, Norys A, Spears, Camille, Smith, Christopher, Flores, John Michael, Taylor, Barbara S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255592/
http://dx.doi.org/10.1093/ofid/ofy210.576
_version_ 1783373977709707264
author Matheu, Michelle
Gleason, Laurie
Sunil, Thankam
Castro-Pena, Norys A
Spears, Camille
Smith, Christopher
Flores, John Michael
Taylor, Barbara S
author_facet Matheu, Michelle
Gleason, Laurie
Sunil, Thankam
Castro-Pena, Norys A
Spears, Camille
Smith, Christopher
Flores, John Michael
Taylor, Barbara S
author_sort Matheu, Michelle
collection PubMed
description BACKGROUND: HIV-related stigma is a leading barrier to engagement in HIV care and successful treatment. Disclosure Stigma (DS), the fear of disclosing one’s serostatus, is associated with poor adherence and retention in care, but its association with clinical indicators of HIV treatment is not well established. The purpose of this study was to determine the influence of DS on virologic suppression, and our hypothesis was that DS would be associated with lack of virologic suppression. METHODS: This cross-sectional study was performed between May 2015 and February 2016, at the largest publicly funded HIV clinic in South Texas. A survey was administered to consecutively recruited participants at routine follow-up who were: ≥18-years-old, HIV+, and receiving antiretroviral therapy. Surveys included demographics, sexual/HIV history, AIDS Clinical Trials Group baseline adherence questionnaire, and a validated HIV-stigma scale. Clinical data were obtained from medical records. The primary predictor was DS: the sum of 10 items ranked 0–4, with maximum score of 30 indicating highest stigma. The primary outcome was lack of virologic suppression (LOVS): most recent HIV-1 RNA>20 copies/mL. Bivariate analyses were conducted to examine: (i) predictors of DS and (ii) predictors of LOVS. Multivariate logistic regression models examined the relationship between DS and LOVS. RESULTS: For 275 participants, median DS score was 18.5 (IQR 13, 23). In bivariate analysis, depression (OR 1.10; CI 1.05, 1.15) and perceived stress (OR 1.04; CI 1.01, 1.08) were significantly associated with increased DS. However, dissatisfaction with help received by friends/family was associated with reduced odds of DS (OR 0.46; CI 0.27, 0.78). DS was significantly inversely associated with LOVS (OR 0.96; CI 0.92, 0.99) and age (OR 0.97; CI 0.95, 0.998), and positively associated with drug use (OR 3.96; CI 1.53, 10.23). The association between DS and LOVS was maintained after adjusting for age, gender/sexual orientation, race/ethnicity, and drug use. CONCLUSION: DS was highly prevalent in this cohort. The unanticipated inverse association between DS and LOVS highlights the complexity of this relationship. Despite this association, the balance of data in this cohort demonstrates an overall negative impact of DS. Further study is needed to understand this surprising finding. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6255592
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62555922018-11-28 568. The Impact of Disclosure Stigma on Virologic Outcomes in People Living with HIV Matheu, Michelle Gleason, Laurie Sunil, Thankam Castro-Pena, Norys A Spears, Camille Smith, Christopher Flores, John Michael Taylor, Barbara S Open Forum Infect Dis Abstracts BACKGROUND: HIV-related stigma is a leading barrier to engagement in HIV care and successful treatment. Disclosure Stigma (DS), the fear of disclosing one’s serostatus, is associated with poor adherence and retention in care, but its association with clinical indicators of HIV treatment is not well established. The purpose of this study was to determine the influence of DS on virologic suppression, and our hypothesis was that DS would be associated with lack of virologic suppression. METHODS: This cross-sectional study was performed between May 2015 and February 2016, at the largest publicly funded HIV clinic in South Texas. A survey was administered to consecutively recruited participants at routine follow-up who were: ≥18-years-old, HIV+, and receiving antiretroviral therapy. Surveys included demographics, sexual/HIV history, AIDS Clinical Trials Group baseline adherence questionnaire, and a validated HIV-stigma scale. Clinical data were obtained from medical records. The primary predictor was DS: the sum of 10 items ranked 0–4, with maximum score of 30 indicating highest stigma. The primary outcome was lack of virologic suppression (LOVS): most recent HIV-1 RNA>20 copies/mL. Bivariate analyses were conducted to examine: (i) predictors of DS and (ii) predictors of LOVS. Multivariate logistic regression models examined the relationship between DS and LOVS. RESULTS: For 275 participants, median DS score was 18.5 (IQR 13, 23). In bivariate analysis, depression (OR 1.10; CI 1.05, 1.15) and perceived stress (OR 1.04; CI 1.01, 1.08) were significantly associated with increased DS. However, dissatisfaction with help received by friends/family was associated with reduced odds of DS (OR 0.46; CI 0.27, 0.78). DS was significantly inversely associated with LOVS (OR 0.96; CI 0.92, 0.99) and age (OR 0.97; CI 0.95, 0.998), and positively associated with drug use (OR 3.96; CI 1.53, 10.23). The association between DS and LOVS was maintained after adjusting for age, gender/sexual orientation, race/ethnicity, and drug use. CONCLUSION: DS was highly prevalent in this cohort. The unanticipated inverse association between DS and LOVS highlights the complexity of this relationship. Despite this association, the balance of data in this cohort demonstrates an overall negative impact of DS. Further study is needed to understand this surprising finding. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6255592/ http://dx.doi.org/10.1093/ofid/ofy210.576 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Matheu, Michelle
Gleason, Laurie
Sunil, Thankam
Castro-Pena, Norys A
Spears, Camille
Smith, Christopher
Flores, John Michael
Taylor, Barbara S
568. The Impact of Disclosure Stigma on Virologic Outcomes in People Living with HIV
title 568. The Impact of Disclosure Stigma on Virologic Outcomes in People Living with HIV
title_full 568. The Impact of Disclosure Stigma on Virologic Outcomes in People Living with HIV
title_fullStr 568. The Impact of Disclosure Stigma on Virologic Outcomes in People Living with HIV
title_full_unstemmed 568. The Impact of Disclosure Stigma on Virologic Outcomes in People Living with HIV
title_short 568. The Impact of Disclosure Stigma on Virologic Outcomes in People Living with HIV
title_sort 568. the impact of disclosure stigma on virologic outcomes in people living with hiv
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255592/
http://dx.doi.org/10.1093/ofid/ofy210.576
work_keys_str_mv AT matheumichelle 568theimpactofdisclosurestigmaonvirologicoutcomesinpeoplelivingwithhiv
AT gleasonlaurie 568theimpactofdisclosurestigmaonvirologicoutcomesinpeoplelivingwithhiv
AT sunilthankam 568theimpactofdisclosurestigmaonvirologicoutcomesinpeoplelivingwithhiv
AT castropenanorysa 568theimpactofdisclosurestigmaonvirologicoutcomesinpeoplelivingwithhiv
AT spearscamille 568theimpactofdisclosurestigmaonvirologicoutcomesinpeoplelivingwithhiv
AT smithchristopher 568theimpactofdisclosurestigmaonvirologicoutcomesinpeoplelivingwithhiv
AT floresjohnmichael 568theimpactofdisclosurestigmaonvirologicoutcomesinpeoplelivingwithhiv
AT taylorbarbaras 568theimpactofdisclosurestigmaonvirologicoutcomesinpeoplelivingwithhiv